Browse by category

Post hoc analyses from the phase 3 REDEFINE 1 trial evaluating CagriSema, an investigational injectable combination treatment for adults with overweight or obesity, and its effects on well-known cardiovascular (CV) risk factors, has revealed that systolic blood pressure was reduced by -10.9 mmHg over 68 weeks (versus -8.8 mmHg with semaglutide 2.4 mg and -2.1 mmHg with placebo). This reduction was seen regardless of BMI (less than versus greater than or equal to 35 kg/m2). In

Eli Lilly and Company has announced an agreement with the US government to expand access to its obesity medicines and reduce patient costs. In 2020, Lilly partnered with the Trump Administration on a pilot programme that paved the way for Lilly to be the first company to cap out-of-pocket insulin costs at $35 per month. Lilly will now improve access to nearly 40 million Americans living with obesity on government insurance programmes and millions more who pay out-of-pocket. U

Nitinotes has received CE Mark approval for the EndoZip System, the first fully automated suturing platform for endoscopic sleeve gastroplasty (ESG). The milestone clearance enables the company to begin commercialisation across the European Union and other CE Mark-accepting markets. Nitinotes will launch EndoZip in select European centres of excellence, building clinical adoption and real-world data to support broader market penetration. In parallel, the company is preparing

Researchers from the University of Liverpool, using the first modelled estimate to date shows how mandatory nutrition labelling could impact obesity prevalence and mortality in England's population, have found that making front-of-pack nutrition labelling mandatory could significantly reduce obesity rates and save thousands of lives across England. Using a microsimulation model, the team examined the effects of introducing either mandatory traffic light or nutrient warning la

For patients living with mild-to-moderate obesity, newer obesity management medications (OMM) such as tirzepatide and semaglutide, appear to be valid alternatives to endoscopic bariatric procedures (EBP) and metabolic bariatric surgery (MBS), according to researchers from the Italian Obesity Society (Società Italiana dell'Obesità (SIO)). Their study reveals the results from a systematic review (SR) and a network meta-analysis (NMA) on randomised clinical trials (RCTs) compari

Phenomix Sciences has announced results from new research, presented at Obesity Week 2025, demonstrating the continued clinical utility of its MyPhenome test, backed by a proprietary machine-learning Genetic Risk Score (GRS), in predicting obesity and treatment outcomes across large and diverse patient populations. The studies, led by Mayo Clinic researcher and Phenomix co-founder Dr Andres Acosta, further validate the MyPhenome test's ability to predict patient response to G

Welcome to our regular round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have looked far and wide to give you an overview of papers including MBS is independently associated with improved survival in individuals aged 69 years and older, re-sleeve gastrectomy associated with significantly higher rates of serious perioperative complications, conversion to open in bariatric surgery associated with significant increased r

Apnimed has announced positive results from the Phase 2 FLOW study evaluating sulthiame, a differentiated, once-daily oral carbonic anhydrase inhibitor, in the treatment of obstructive sleep apnoea (OSA). The study demonstrated that sulthiame significantly improved important OSA metrics in adults with moderate to severe OSA. Sulthiame has a different mechanism of action from Apnimed's lead programme, AD109, with the potential to address other aspects of the pathophysiology of

Researchers from Singapore General Hospital (SGH) and National University of Singapore (NUS) have reported that using pulsed electromagnetic fields to stimulate muscle tissue and mimic the effects of exercise, could benefit patients with type 2 diabetes with excess abdominal fat. Magnetic mitohormesis device used to deliver low-dose PEMF. The device measures 50 cm (W) × 60 cm (L) × 110 cm (H), with a treatment chamber with an internal diameter of 26 cm and a depth of 50 cm. C

Treatment for obesity in the UK could become a two-tier system where the most vulnerable patients miss out altogether, obesity experts from King's College London and the Obesity Management Collaborative (OMC-UK) have warned. They stated that strict eligibility criteria means that only a small number of people will have access to the weight loss drug tirzepatide (Mounjaro) on the NHS, with those able to afford it paying privately for treatment. The researchers argue, in an edi